Forbion - Home

At Forbion Capital Partners we invest in Life Sciences and Biomedical Technology companies developing world-class drugs and technologies, with a clear focus on product development.

Learn more »

'For Biotech and Beyond'

16.05.2012 Promedior Appoints Suzanne L. Bruhn, Ph.D., as President and Chief Executive Officer » 24.04.2012 arGEN-X Granted first US patent covering its unique NHance™ technology » 24.04.2012 Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012 »

Pictures